Rubella virus envelope glycoprotein E2 (E2)

Rubella virus envelope glycoprotein E2 is a critical structural component of the rubella virus, a member of the Matonaviridae family. It is a type I transmembrane glycoprotein that forms a stable heterodimeric complex with the E1 glycoprotein on the viral surface, which is essential for viral infectivity and structural integrity (UniProt P08563). E2 is primarily involved in the early stages of infection, including attachment to host cell receptors and facilitating the transport of the E1-E2 complex through the secretory pathway during viral assembly (PubMed: 11836333). As a major surface antigen, E2 is a key target for the host's humoral immune response; neutralizing antibodies directed against E2 can prevent the virus from entering host cells (PubMed: 2493514). While no specific small-molecule antivirals currently target E2, it is a fundamental component of the live-attenuated rubella vaccines used globally to prevent Rubella and Congenital Rubella Syndrome (CDC, 2021). Monitoring anti-E2 antibody titers is a standard clinical practice to determine immune status and diagnose recent infections (WHO, 2019).

Other names

E2 glycoproteinp30Rubella virus E2 proteinEnvelope glycoprotein E2

Vaccines containing live-attenuated rubella virus induce the production of neutralizing antibodies specifically targeting the E2 and E1 glycoproteins, thereby blocking viral entry into host cells and providing long-term immunity (CDC, 2021). Passive immunization with Rubella Immune Globulin provides immediate but temporary neutralizing antibodies to prevent or attenuate infection (WHO, 2019).